Ligand Pharmaceuticals Inc.

430 articles with Ligand Pharmaceuticals Inc.

• Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors

  10/15/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a privately held biotechnology company pioneering the use of antibody-oligonucleotide conjugates (AOC™) to treat rare muscle disorders and other serious diseases.

• Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference

  8/29/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York City. Presentation takes place on Tuesday, September 10, 2019 at 8:45 a.m. Eastern Time.

• Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China

  8/12/2019

  It is the only approved melphalan product available in China.

• Ligand Reports Second Quarter 2019 Financial Results

  7/30/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2019, and provided an operating forecast and program updates.

• Ligand to Report Second Quarter 2019 Results on July 30th

  7/15/2019

  Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call.

• Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

  7/10/2019

  Study achieved primary endpoint demonstrating pharmacokinetic bioequivalence between Captisol-enabled Iohexol and OMNIPAQUE™

• Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation - July 8, 2019

  7/8/2019

  Ligand Pharmaceuticals Incorporated and SQ Innovation AG announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of Ligand’s Captisol® technology in the formulation of high-concentration furosemide for the treatment of edema in patients with heart failure.

• Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

  7/8/2019

  Ligand Pharmaceuticals Incorporated and SQ Innovation AG announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of Ligand's Captisol® technology in the formulation of high-concentration furosemide for the treatment of edema in patients with heart failure.

• ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics

  7/1/2019

  ZULRESSO is the 11th FDA-approved drug to use Ligand’s patented Captisol technology.

• Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target

  6/12/2019

  Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.

• Ligand Licenses VER250840 to Cumulus Oncology

  5/17/2019

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP)

• Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.

  5/6/2019

  Phase 3 drug candidate targeting molluscum

• Ligand Reports First Quarter 2019 Financial Results

  5/2/2019

  Conference Call Begins at 4:30 p.m. Eastern Time Today

• Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol

  5/2/2019

  Also reports recent results from clinician survey on radiocontrast agent selection and use

• Ligand to Report First Quarter 2019 Results on May 2nd

  4/18/2019

  Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

• Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection

  3/21/2019

  ZULRESSO is the first and only treatment specifically indicated for postpartum depression

• Ligand to Participate in Four Upcoming Investor Conferences

  3/12/2019

  Ligand Pharmaceuticals Incorporated announces that company executives are scheduled to participate in the following upcoming investor conferences

• Ligand Provides Highlights from Today’s Analyst Day Event - March 12, 2019

  3/12/2019

  At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated reviewed the recent progress of its business and financial growth outlook.

• Ligand Sells Promacta Assets and Royalty for $827 Million

  3/5/2019

  Ligand Pharmaceuticals Incorporated and Royalty Pharma announce the sale of Ligand’s Promacta®-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827 million in cash.

• Reminder: Ligand to Host Analyst Day on March 12th in New York City

  2/21/2019

  Event to feature business updates and presentations by four corporate partners